San Antonio Breast Cancer Symposium | Conference

Dr. Perez on the Phase III Eribulin/Capecitabine Study

January 9th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Dr. Gradishar Discusses 10 Years of Adjuvant Tamoxifen

January 4th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, discusses results from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.

Dr. Arteaga on Key Takeaway Points From the 2012 SABCS

December 10th 2012

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

2012 San Antonio Breast Cancer Symposium Photos

December 10th 2012

Photos from the 35th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 4-8, 2012.

Cognitive Impairment Previously Linked to Chemotherapy May Originate Before Treatment

December 8th 2012

The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."

Dr. Twelves Compares Eribulin and Capecitabine

December 8th 2012

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

Justin Balko on the Diversity of Genetic Alterations in TNBC

December 8th 2012

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

Long-Term Follow-Up Supports Use of Hypofractionated Radiotherapy in Early-Stage Breast Cancer

December 7th 2012

Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.

Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care

December 7th 2012

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

Dr. Yarnold on Hypofractionation in the START Trials

December 7th 2012

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

Adjuvant Bevacizumab Falls Short in Triple-Negative Breast Cancer

December 7th 2012

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

Dr. Leyland-Jones Discusses the Phase III HERA Trial

December 7th 2012

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Study Shows Eribulin Not Superior to Capecitabine in Previously Treated Metastatic Breast Cancer

December 7th 2012

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

December 6th 2012

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

December 6th 2012

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Dr. Aebi on Adjuvant Chemo in Recurrent Breast Cancer

December 6th 2012

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

HDAC Inhibition Appears to Sensitize Triple-Negative Breast Cancer Cells to Certain Treatments

December 6th 2012

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant Chemotherapy Improves Survival in Women With Recurrent Breast Cancer

December 6th 2012

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

December 5th 2012

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

December 5th 2012

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

NEXT PAGE
PREVIOUS PAGE